Antacids containing aluminum and magnesium, antidiarrheals, phenobarbital: Phar-macokinetic alterations and subsequent de-creased therapeutic response to haloperidol may follow concomitant use. Monitor child closely.
Antiarrhythmics, disopyramide, procainamide, quinidine: Increased risk of arrhythmias and con-duction defects. Use with extreme caution; mon-itor child closely.
Anticholinergics, atropine: Oversedation, para-lytic ileus, visual changes, severe constipation. Avoid concomitant use.
Appetite suppressants, sympathomimetics (such as ephedrine, epinephrine, phenylephrine, phenylpropanolamine): May decrease stimula-tory and pressor effects of these drugs. Monitor child closely.
Beta blockers: May inhibit haloperidol metabo-lism, increasing plasma levels and toxicity. Mon-itor haloperidol levels.
Bromocriptine: Haloperidol may antagonize ther-apeutic effect. Monitor child closely.
Centrally acting antihypertensive drugs (such as clonidine, guanabenz, guanadrel, guanethidine, methyldopa, reserpine): Haloperidol may inhibit blood pressure response to these drugs. Check blood pressure frequently.
CNS depressants; epidural, general, or spinal anesthetics: Increased CNS depression. Avoid concomitant use.
Dopamine: May decrease vasoconstricting effects of high-dose dopamine. Monitor blood pressure.
Levodopa: May decrease effectiveness and in-crease toxicity of levodopa. Use together cau-tiously.
Lithium: May result in severe neurologic toxicity with encephalitis-like syndrome and decreased therapeutic response to haloperidol. Monitor child.
Nitrates: May cause hypotension. Monitor blood pressure closely.
Parenteral magnesium sulfate: Possible over. sedation, respiratory depression, and hypoten-sion. Avoid concomitant use.
Phenytoin: May inhibit metabolism and increase toxicity of phenytoin. Monitor phenytoin levels.
Propylthiouracil: Increased risk of agranulocytosis with concomitant use. Monitor child closely. Drug-herb. |